News
REPL
10.23
+7.46%
0.71
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 3d ago
Weekly Report: what happened at REPL last week (0706-0710)?
Weekly Report · 6d ago
‘Blue Sky’ Ahead? J.P. Morgan Picks 2 Stocks to Buy for the Rest of 2026
TipRanks · 07/10 09:59
Replimune Group put volume heavy and directionally bearish
TipRanks · 07/08 16:35
Weekly Report: what happened at REPL last week (0629-0703)?
Weekly Report · 07/06 09:09
Four stock-moving events to watch as FDA revives AdComs
Seeking Alpha · 07/01 17:51
Midday Fly By: Patrick to combine with LCI, AeroVironment reports Q4 beat
TipRanks · 06/30 16:05
Replimune: Stock Buoyant On Third Try At RP1 Approval - FDA AdCom May Be Crucial
Seeking Alpha · 06/30 14:09
Video: AeroVironment jumps after Q4 earnings beat
TipRanks · 06/30 13:10
Darden Restaurants To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 06/30 13:04
Replimune Group Is Maintained at Neutral by Wedbush
Dow Jones · 06/30 13:01
Replimune Group Price Target Raised to $9.00/Share From $6.00 by Wedbush
Dow Jones · 06/30 13:01
Wedbush Maintains Neutral on Replimune Group, Raises Price Target to $9
Benzinga · 06/30 12:51
Analysts Offer Insights on Healthcare Companies: Replimune Group (REPL), Abivax SA Sponsored ADR (ABVX) and Larimar Therapeutics (LRMR)
TipRanks · 06/30 12:10
Replimune price target raised to $9 from $6 at Wedbush
TipRanks · 06/30 11:50
BMO double upgrades Replimune on higher chances of FDA approval
TipRanks · 06/30 11:00
REPLIMUNE GROUP INC <REPL.O>: BMO RAISES TO OUTPERFORM FROM UNDERPERFORM
Reuters · 06/30 10:50
Signs of Economic Resilience Boost Stocks
Barchart · 06/30 10:10
Stock Indexes Supported by Strong Demand for Technology Stocks
Barchart · 06/30 08:59
More
Webull provides a variety of real-time REPL stock news. You can receive the latest news about Replimune Group through multiple platforms. This information may help you make smarter investment decisions.
About REPL
Replimune Group, Inc. is a clinical-stage biotechnology company engaged in the development of novel oncolytic immunotherapies. Its proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor-derived antigens and altering of the tumor microenvironment to ignite a systemic response. Its lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF. Its lead indication for its lead product candidate, RP1, is the potential treatment of advanced melanoma. Its pipeline product candidates include RP2 and RP3. It has designed its RP2 product candidate to express an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response.